Targeting miR-21 in glioma: a small RNA with big potential

Bibliography

• Louis DN, Ohgaki H, Wiestler OD, The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 2007;114(2):97-109
   PubMed Web of Science ®Google Scholar
• Collins VP. Mechanisms of disease: genetic predictors of response to treatment in brain tumors. Nat Clin Prac Oncol 2007;4(6):362-74
   PubMedGoogle Scholar
• Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane database syst Rev 2008;(2):CD007104 (2008): doi: 10.1002/14651858.CD007104
   Google Scholar
• Reardon DA, Wen PY, Desjardins A, Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 2008;8(4):541-53
   PubMed Web of Science ®Google Scholar
• Steinert DM, McAuliffe JC, Trent JC. Imatinib mesylate in the treatment of gastrointestinal stromal tumour. Expert opin pharmacother 2005;6(1):105-13
   PubMedGoogle Scholar
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170(5):1445-53
   PubMed Web of Science ®Google Scholar
• Fleming TP, Saxena A, Clark WC, Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52(16):4550-3
   PubMedGoogle Scholar
• Maher EA, Furnari FB, Bachoo RM, Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15(11):1311-33
   PubMedGoogle Scholar
• Rich JN, Reardon DA, Peery T, Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22(1):133-42
   PubMed Web of Science ®Google Scholar
• de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008;14(5):279-85
   PubMedGoogle Scholar
• Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004;431(7006):343-9
   PubMedGoogle Scholar
• Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucl Acids Res 2008;36(Suppl_1):D154-58
   Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD, Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101(9):2999-3004
   PubMedGoogle Scholar
• Lu J, Getz G, Miska EA, MicroRNA expression profiles classify human cancers. Nature 2005;435(7043):834-8
   PubMedGoogle Scholar
• Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009;60(1):167-79
   PubMedGoogle Scholar
• Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65(14):6029-33
   PubMedGoogle Scholar
• Ciafre SA, Galardi S, Mangiola A, Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005;334(4):1351-8
   PubMedGoogle Scholar
• Conti A, Aguennouz M, La Torre D, miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol 2009;93(3):325-32
   PubMedGoogle Scholar
• Bastian M, Marietta W, Franziska L, Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 2010;20(3):539-50
   PubMedGoogle Scholar
• Gabriely G, Wurdinger T, Kesari S, MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008;28(17):5369-80
   PubMedGoogle Scholar
• Gao W, Yu Y, Cao H, Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010;64(6):399-408
   PubMedGoogle Scholar
• Hwang JH, Voortman J, Giovannetti E, Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010;5(5):e10630
   Google Scholar
• Rossi S, Shimizu M, Barbarotto E, microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010;116(6):945-52
   PubMedGoogle Scholar
• Slaby O, Lakomy R, Fadrus P, MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 2010;57(3):264-9
   PubMedGoogle Scholar
• Lee Y, Kim M, Han J, MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23(20):4051-60
   PubMedGoogle Scholar
• Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006;13(12):1097-101
   PubMedGoogle Scholar
• Winter J, Jung S, Keller S, Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11(3):228-34
   PubMed Web of Science ®Google Scholar
• Lee Y, Ahn C, Han J, The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425(6956):415-19
   PubMed Web of Science ®Google Scholar
• Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003;17(24):3011-16
   PubMed Web of Science ®Google Scholar
• Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409(6818):363-6
   PubMed Web of Science ®Google Scholar
• Schwarz DS, Hutvagner G, Du T, Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003;115(2):199-208
   PubMed Web of Science ®Google Scholar
• Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008;454(7200):56-61
   PubMed Web of Science ®Google Scholar
• Fujita S, Ito T, Mizutani T, miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol 2008;378(3):492-504
   PubMedGoogle Scholar
• Wang K, Li P-F. Foxo3a regulates apoptosis by negatively targeting miR-21. J Biol Chem 2010;285(22):16958-66
   PubMedGoogle Scholar
• Loffler D, Brocke-Heidrich K, Pfeifer G, Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110(4):1330-3
   PubMedGoogle Scholar
• Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19(21):2474-88
   PubMed Web of Science ®Google Scholar
• Rahaman SO, Harbor PC, Chernova O, Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002;21(55):8404-13
   PubMedGoogle Scholar
• Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005;33(4):1290-7
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Wehbe-Janek H, MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133(2):647-58
   PubMed Web of Science ®Google Scholar
• Asangani IA, Rasheed SAK, Nikolova DA, MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2007;27(15):2128-36
   PubMedGoogle Scholar
• Zhu S, Si M-L, Wu H, Mo Y-Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). Journal of Biological Chemistry 2007;282(19):14328-36
   PubMed Web of Science ®Google Scholar
• Sayed D, He M, Hong C, MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 2010;285(26):20281-90
   PubMedGoogle Scholar
• Li Y, Li W, Yang Y, MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 2009;1286:13-18
   PubMed Web of Science ®Google Scholar
• Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008;68(19):8164-72
   PubMedGoogle Scholar
• Zhang H, Ozaki I, Mizuta T, Involvement of programmed cell death 4 in transforming growth factor-beta 1-induced apoptosis in human hepatocellular carcinoma. Oncogene 2006;25(45):6101-12
   PubMedGoogle Scholar
• Chen Y, Liu W, Chao T, MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett 2008;272(2):197-205
   PubMedGoogle Scholar
• Frankel LB, Christoffersen NR, Jacobsen A, Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. The J Biol Chem 2008;283(2):1026-33
   PubMed Web of Science ®Google Scholar
• Gao F, Zhang P, Zhou C, Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma. Oncol Rep 2007;17(1):123-8
   PubMedGoogle Scholar
• Zhou X, Ren Y, Moore L, Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest 2010;90(2):144-55
   PubMedGoogle Scholar
• Lee SY, Lee SY, Choi Y. TRAF-interacting Protein (TRIP): A novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J Exp Med 1997;185(7):1275-86
   PubMedGoogle Scholar
• Connolly EC, Van Doorslaer K, Rogler LE, Rogler CE. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol Cancer Res 2010;8(5):691-700
   PubMedGoogle Scholar
• Li T, Li D, Sha J, MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009;383(3):280-5
   PubMed Web of Science ®Google Scholar
• Liu M, Wu H, Liu T, Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res 2009;19(7):828-37
   PubMedGoogle Scholar
• Qin W, Zhao B, Shi Y, BMPRII is a direct target of miR-21. Acta Biochim Biophys Sin (Shanghai) 2009;41(7):618-23
   PubMedGoogle Scholar
• Wang P, Zou F, Zhang X, microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 2009;69(20):8157-65
   PubMedGoogle Scholar
• Thum T, Gross C, Fiedler J, MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456(7224):980-4
   PubMed Web of Science ®Google Scholar
• Corsten MF, Miranda R, Kasmieh R, MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 2007;67(19):8994-9000
   PubMedGoogle Scholar
• Ren Y, Zhou X, Mei M, MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010;10:27
   PubMed Web of Science ®Google Scholar
• Shi L, Chen J, Yang J, MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010;1352:255-64
   PubMed Web of Science ®Google Scholar
• Ren Y, Kang CS, Yuan XB, Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 2010;21(3):303-14
   PubMedGoogle Scholar
• Mei M, Ren Y, Zhou X, Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat 2010;9(1):77-86
   PubMedGoogle Scholar
• Lennox K, Behlke M. A Direct comparison of anti-microRNA oligonucleotide potency. Pharm Res 2010;27(9):1788-99
   PubMedGoogle Scholar
• Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006;34(8):2294-304
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Schutz S, LNA-mediated microRNA silencing in non-human primates. Nature 2008;452(7189):896-9
   PubMedGoogle Scholar
• Krutzfeldt J, Rajewsky N, Braich R, Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005;438(7068):685-9
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J, Kuwajima S, Braich R, Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 2007;35(9):2885-92
   PubMedGoogle Scholar
• Stommel JM, Kimmelman AC, Ying H, Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318(5848):287-90
   PubMed Web of Science ®Google Scholar